Paper Details

  1. Home
  2. Paper Details

Tiotropium HandiHaler in the treatment of COPD: a safety review.

Author: CelliBart, DecramerMarc, KestenSteven, LeimerInge, TashkinDonald

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Tiotropium, a long-acting inhaled anticholinergic for treating chronic obstructive pulmonary disease (COPD), has been available since 2002. This study updates an evaluation of the safety of tiotropium in the HandiHaler formulation based on new clinical trial data.
Paper Details　
Original Abstract of the Article :
Tiotropium is a long-acting inhaled anticholinergic developed for the treatment of chronic obstructive pulmonary disease (COPD) and has been available since 2002. We sought to update an evaluation of the safety of tiotropium in the HandiHaler formulation as significant clinical trial data have becom...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793068/

データ提供：米国国立医学図書館（NLM）

Tiotropium HandiHaler: A Safe and Effective Treatment for COPD

Chronic obstructive pulmonary disease (COPD) is a serious respiratory condition that can significantly affect quality of life. This research reviews the safety of tiotropium, a long-acting inhaled anticholinergic, in the HandiHaler formulation, a popular treatment option for COPD. The review analyzed a significant amount of clinical trial data to assess the safety profile of tiotropium HandiHaler. The findings suggest that tiotropium HandiHaler is a safe and effective treatment for COPD with a favorable safety profile.

Tiotropium HandiHaler: A Reliable Treatment Option for COPD

This safety review provides reassuring evidence for the use of tiotropium HandiHaler in managing COPD. The findings highlight the safety and effectiveness of this treatment option, offering hope for patients seeking relief from COPD symptoms. The review emphasizes the importance of careful monitoring and individualized treatment plans to optimize patient outcomes.

Managing COPD: A Comprehensive Approach

COPD is a complex condition, and managing it effectively requires a multi-faceted approach. This review underscores the role of tiotropium HandiHaler as a safe and effective treatment option for COPD, providing valuable information for healthcare providers and patients. It’s like navigating a desert landscape; a combination of strategies, including medication and lifestyle modifications, can help patients manage COPD and improve their quality of life.

Dr. Camel's Conclusion

COPD can be a harsh desert wind, but tiotropium HandiHaler offers a safe and effective oasis, providing relief from the symptoms of this challenging respiratory condition. This comprehensive safety review offers reassurance for patients and healthcare providers alike, highlighting the reliability of this treatment option.

Date :
  1. Date Completed 2010-03-17
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20037679

DOI: Digital Object Identifier

PMC2793068

Related Literature

Article Analysis
・Side Effects of tiotropium oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.